Evidence map›Paper›PMID 42081121›Full record

Observational studyEndocrine2026

Short-term effect of tirzepatide on serum calcitonin in adults with obesity.

Nikolaos Angelopoulos, George Simeakis, Ioannis Androulakis, Andreas Rizoulis, Anastasios Boniakos, Paraskevi Mentzelopoulou, Areti Korakovouni, Dimitra Zianni, Valentina Petkova, Sarantis Livadas and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nikolaos AngelopoulosHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece. drangelnick@gmail.com.ORCID 0000-0002-8901-7161
George SimeakisEndocrine Department, 401 General Military Hospital of Athens, Athens, 11525, Greece.
Ioannis AndroulakisHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Andreas RizoulisHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Anastasios BoniakosHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Paraskevi MentzelopoulouHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Areti KorakovouniHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Dimitra ZianniHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Valentina PetkovaHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Sarantis LivadasHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.
Rodis PaparodisHellenic Endocrine Network, Ermou 6 Str, Athens, 10563, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate whether short-term treatment with tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with measurable changes in serum calcitonin levels in adults with obesity and no known thyroid disease.

methodsIn this prospective observational study, 58 adults (mean age 47.5 ± 10.7 years; 72% female; mean BMI 41.4 ± 8.1 kg/m²) initiated tirzepatide therapy for weight loss. Serum calcitonin concentrations were measured at baseline and after 12 weeks of treatment. Secondary parameters included HbA1c and estimated glomerular filtration rate (eGFR).

resultsMean baseline calcitonin was 2.7 ± 3.0 pg/mL, increasing to 3.2 ± 3.7 pg/mL post-treatment. This change was statistically significant (Wilcoxon Z = − 3.0, p = 0.003) with a moderate effect size (r = 0.4), despite a small absolute increase. No participant exceeded the clinical calcitonin threshold of 20 pg/mL. No thyroid nodules were detected on ultrasound.

conclusionTirzepatide treatment over 12 weeks was associated with a modest but statistically significant increase in serum calcitonin levels in adults with obesity. However, absolute values remained within the normal range, and no clinically relevant thyroid abnormalities were observed. These findings support the short-term safety of tirzepatide in appropriately selected patients without known thyroid disease or risk factors for medullary thyroid carcinoma.

Indexed as

CalcitoninGlucagon-Like Peptide-1 Receptor AgonistsObesityTirzepatideAdultFemaleHumansMaleMiddle AgedProspective StudiesWeight LossCalcitoninGlucagon-Like Peptide-1 Receptor AgonistsTirzepatideCalcitoninGLP-1 receptor agonistsGlucose-dependent insulinotropic polypeptide (GIP)Medullary thyroid carcinomaObesityTirzepatide

Identifiers

PMID42081121

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.